Robert Shiller Says Stocks Are Overvalued Again

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Yale's Robert Shiller made headlines by predicting the bursting of the bubble. More recently, he's been associated with the S&P Case-Shiller Home Price Index. He's also known for valuing stocks with P/E ratios that use trailing-10-year EPS to smooth out bumps in the business cycle. Some refer to this method as "P/E10."

Now he's at odds with Wall Street, saying that stocks are currently pricey by historical measures. His calculations differ from Wall Street's. You may already know Shiller uses P/E10 to value stocks. What you may not know is that he values stocks based on GAAP (Generally Accepted Accounting Principles) earnings instead of "operating" earnings, the earnings before bad stuff that Wall Street favors.

By his calculations, the P/E ratio on the S&P 500 Index is 23x. That's more than 40% higher than its long-term average of 16x. Based on "operating" earnings for the most recent four quarters, Wall Street says the S&P 500 Index is trading at a much more attractive P/E ratio of 14x.

The case for P/E10
It's not just revenue growth that varies with economic cycles. Profit margins do, too. Margins have been rising and are near record levels. In the fourth quarter of 2010 profit margins for S&P 500 Index members were 8.2%, well above the 15-year average of 6.1%.

Profit margins are mean reverting, or in plain English, what goes up must come down. The difference between 8.2% and 6.1% may not sound like much, but reverting to the 15-year average from current levels would reduce profits by a whopping 26% (all else being equal).

Taking a long-term view by using trailing-10-year EPS to value stocks is a good way to smooth out these variances and identify risky prices.

The case for GAAP earnings
How big is the difference between operating and GAAP earnings... the "GAAP gap"? That depends. For quarters since 1988, GAAP EPS has ranged from a low of 25% of operating EPS to a high of 109% with a median of 92%. For 2010 it was a median 92%.

Importantly, the GAAP gap varies tremendously by company and market sector. Last year, the difference was most egregious for the health-care sector, followed by financials and utilities (see table). The GAAP gap gave P/E ratios in those sectors a nasty boost. For example, at the end of 2010 the P/E ratio on the health-care sector was 12.6x based on operating EPS (Wall Street's "before bad stuff" view), but a far less compelling 16.2x based on GAAP EPS.


Operating EPS

Operating P/E


S&P 500




S&P 500 Consumer Discretionary Sector




S&P 500 Consumer Staples Sector




S&P 500 Energy Sector




S&P 500 Financials Sector




S&P 500 Health-Care Sector




S&P 500 Industrials Sector




S&P 500 Information Technology Sector




S&P 500 Materials Sector




S&P 500 Telecommunication Services Sector




S&P 500 Utilities Sector




Source: Standard & Poor's and the Motley Fool.

Does that mean you should sell your health-care stocks? No. The GAAP gap varies a great deal among companies, even within the same sector. Let's go sector diving and see how it shakes out for the biggest companies in the three sectors with the most egregious GAAP gaps. In the following table, the GAAP gap is "GAAP EPS % of Operating EPS". Lower numbers are worse.


GAAP EPS % of Operating EPS

Operating P/E






Pfizer (NYSE: PFE  )




Johnson & Johnson




Merck & Co. (NYSE: MRK  )








JPMorgan Chase & Co (NYSE: JPM  )




Wells Fargo Company (NYSE: WFC  )




Berkshire Hathaway B








Southern Co. (NYSE: SO  )




Exelon Corp. (NYSE: EXC  )




Dominion Resources (NYSE: D  )




Source: Standard & Poor's, and The Motley Fool as of 4/14/11 closing prices.

Pfizer leads this pack when it comes to quality of earnings, with its GAAP EPS actually greater than operating EPS. That can happen from one-time items such as the sale of a business at a profit, but probably isn't sustainable.

Berkshire Hathaway and Southern Company posted respectable quality of earnings as well, with no difference between GAAP and operating EPS. And JPMorgan, widely viewed as the most solid of the big banks, deserves its reputation by this measure.

On the other hand, Merck's results are pretty scary. If it wasn't enough that operating EPS is so depressed the P/E ratio is 124x, GAAP EPS is a loss. And J&J has a pretty embarrassing GAAP gap for such a respected brand name. What looks like a 12.6x P/E is really a much richer 18.7x. Ouch. Dominion Resources is also notable, with what looks like a very low 8.8x P/E ratio actually 10.8x.

Foolish takeaway
Robert Shiller has demonstrated that he is worth listening to. What's more, he doesn't share Wall Street's conflicts of interest. Shiller thinks the stock market is currently pricey based on historical measures. While overvaluations can persist for extended periods, they have always eventually corrected. And corrections typically happen quickly once they are under way.

But not all sectors or stocks are equally pricey. It is a lot of work to value stocks using Shiller's P/E10 method and GAAP earnings. That said, it pays to know where your stocks stand using Shiller's methods in addition to the easily accessible but rosy view that Wall Street dishes out.

Let us know if there is a stock or group of stocks you want to know more about. If there's enough interest, I'll run a valuation based on P/E10 and GAAP.

The Motley Fool recently introduced a free My Watchlist feature. To stay ahead of the curve and receive up-to-date news on the companies of your choosing, add them to your watchlist today:

Fool contributor Cindy Johnson does not own shares of any stock in this story. She does mind the GAAP gap and 10-year earnings.

Berkshire Hathaway, Exelon, Johnson & Johnson, and Pfizer are Motley Fool Inside Value choices. Berkshire Hathaway is a Motley Fool Stock Advisor pick. Dominion Resources, Johnson & Johnson, and Southern are Motley Fool Income Investorchoices. Motley Fool Options has recommended a covered strangle position on Exelon. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Berkshire Hathaway, JPMorgan Chase &, Johnson & Johnson, and Wells Fargo &. Alpha Newsletter Account, LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (4) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 10, 2011, at 12:16 PM, ronbeasley wrote:

    hmmm..I'd rather pay attention to what the best investors are doing than to a guy who runs theoretical broad-brush models at a university. Haven't seen Schiller on any billionaire lists.

  • Report this Comment On May 10, 2011, at 2:53 PM, jabez1 wrote:

    I understand that Schiller adjusts earnings for inflation using the CPI. There are those who make a good case for proving that the CPI understates inflation and that more realistic measures of inflation put the market PE nearer a 16 or 17.

    Any thoughts or opinions on this?

  • Report this Comment On May 26, 2011, at 10:31 PM, scottsicle wrote:

    Thank you for this valuable article. Prof. Schiller's approach is based on historical data, and he has a lot of credibility. The trouble with overvalued markets is that when they correct, even sectors that are not overvalued tend to get pulled down with the correction. Separately, I would be interested in a Schiller-type analysis of recent Stock Advisor picks.

  • Report this Comment On May 26, 2011, at 10:59 PM, scottsicle wrote:

    Another thing to consider, though, is that looking at a Robert Shiller Chart on Stock Valuations reveals that the market has been overvalued almost continuously for the past 20 years, with one very brief exception. And in most years, it's been more overvalued than it is now. So making the case, for example, that it's time to get out of the market based on current valuations would be debatable. Hard to know what strategy to pursue based on the current Shiller valuation, but thank you again for bringing it up. Perhaps there are overseas markets that are less highly valued and may be better places for investing? If that was true, Global Gains should be doing super, but Stock Advisor - if I understand the MF performance data - still does better. Please consider doing a follow-up article or perhaps a series on strategies for investors in markets that Shiller considers overvalued. Thank you.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1492004, ~/Articles/ArticleHandler.aspx, 10/23/2016 4:21:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:01 PM
D $72.84 Down -0.27 -0.37%
Dominion Resources CAPS Rating: ***
EXC $32.50 Down -0.34 -1.04%
Exelon CAPS Rating: ****
JPM $68.49 Up +0.23 +0.34%
JPMorgan Chase CAPS Rating: ****
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****
SO $50.53 Down -0.19 -0.37%
Southern Company CAPS Rating: ***
WFC $45.09 Up +0.16 +0.36%
Wells Fargo CAPS Rating: ****